OKYO (OKYO Pharma) Cash-to-Debt : 493.50 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. OKYO Pharma's cash to debt ratio for the quarter that ended in Sep. 2024 was 493.50.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, OKYO Pharma could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for OKYO Pharma's Cash-to-Debt or its related term are showing as below:

OKYO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.83 Med: No Debt Max: No Debt
Current: 493.5

During the past 13 years, OKYO Pharma's highest Cash to Debt Ratio was No Debt. The lowest was 1.83. And the median was No Debt.

OKYO's Cash-to-Debt is ranked better than
84.94% of 1481 companies
in the Biotechnology industry
Industry Median: 7.56 vs OKYO: 493.50

OKYO Pharma Cash-to-Debt Historical Data

The historical data trend for OKYO Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

OKYO Pharma Cash-to-Debt Chart

OKYO Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

7.34

69.59

No Debt

1.83

No Debt

OKYO Pharma Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	1.83	N/A	No Debt	493.50

Competitive Comparison of OKYO Pharma's Cash-to-Debt

For the Biotechnology subindustry, OKYO Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OKYO Pharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

OKYO Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

OKYO Pharma's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

OKYO Pharma had no debt ⁽¹⁾.

OKYO Pharma's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.987	/	(0.002	+	0)
	=	493.50

OKYO Pharma (NAS:OKYO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

OKYO Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

OKYO Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

OK10:Germany

Address

14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ

Website

https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Executives

John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: Chief Executive Officer
Gabriele M Cerrone	director, 10 percent owner, officer: Executive Chairman	265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer	director	C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon	director	PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah	officer: Chief Financial Officer	55 PARK LANE, LONDON X0 W1K 1NA